GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MediciNova Inc (NAS:MNOV) » Definitions » EV-to-Revenue

MediciNova (MediciNova) EV-to-Revenue : 13.47 (As of Apr. 28, 2024)


View and export this data going back to 2006. Start your Free Trial

What is MediciNova EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, MediciNova's enterprise value is $13.47 Mil. MediciNova's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $1.00 Mil. Therefore, MediciNova's EV-to-Revenue for today is 13.47.

The historical rank and industry rank for MediciNova's EV-to-Revenue or its related term are showing as below:

MNOV' s EV-to-Revenue Range Over the Past 10 Years
Min: 4.45   Med: 25.48   Max: 2172.12
Current: 13.47

During the past 13 years, the highest EV-to-Revenue of MediciNova was 2172.12. The lowest was 4.45. And the median was 25.48.

MNOV's EV-to-Revenue is ranked worse than
63.12% of 1033 companies
in the Biotechnology industry
Industry Median: 7.66 vs MNOV: 13.47

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-04-28), MediciNova's stock price is $1.31. MediciNova's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.02. Therefore, MediciNova's PS Ratio for today is 65.50.


MediciNova EV-to-Revenue Historical Data

The historical data trend for MediciNova's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MediciNova EV-to-Revenue Chart

MediciNova Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 14.89 - 22.79

MediciNova Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 51.67 22.79

Competitive Comparison of MediciNova's EV-to-Revenue

For the Biotechnology subindustry, MediciNova's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MediciNova's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MediciNova's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where MediciNova's EV-to-Revenue falls into.



MediciNova EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

MediciNova's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=13.467/1
=13.47

MediciNova's current Enterprise Value is $13.47 Mil.
MediciNova's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


MediciNova  (NAS:MNOV) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

MediciNova's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=1.31/0.02
=65.50

MediciNova's share price for today is $1.31.
MediciNova's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.02.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


MediciNova EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of MediciNova's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


MediciNova (MediciNova) Business Description

Traded in Other Exchanges
Address
4275 Executive Square, Suite 300, La Jolla, CA, USA, 92037
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's current strategy is to focus its development activities on therapeutics for neurological disorders and fibrotic diseases.
Executives
Nicole Lemerond director 3 MURRAY HILL ROAD, SCARSDALE NY 10583
Hideki Nagao director 4350 LA JOLLA VILLAGE DRIVE, SUITE 950, SAN DIEGO CA 92122
Jason J Kruger officer: Chief Financial Officer 4275 EXECUTIVE SQUARE, SUITE 300, LA JOLLA CA 92037
Douglas Paulin officer: Chief Financial Officer 4275 EXECUTIVE SQUARE, SUITE 300, LA JOLLA CA 92037
Gaeta Federico C.a. officer: Chief Scientific Officer 4275 EXECUTIVE SQUARE, SUITE 300, LA JOLLA CA 92037
3d Investment Partners Pte. Ltd. 10 percent owner 250 NORTH BRIDGE ROAD, #13-01 RAFFLES CITY TOWER, SINGAPORE U0 179101
3d Opportunity Master Fund 10 percent owner C/O MAPLES CORPORATE SERVICES LIMITED, PO BOX 309, UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Carolyn Beaver director 3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Stepanow Edward C Jr. officer: Chief Financial Officer 4275 EXECUTIVE SQUARE SUITE 300, LA JOLLA CA 92037
Kazuko Matsuda officer: Chief Medical Officer C/O MEDICINOVA, INC., 4275 EXECUTIVE SQUARE, SUITE 650, LA JOLLA CA 92037
Yuichi Iwaki director C/O MEDICINOVA, INC., 4275 EXECUTIVE SQUARE, SUITE 650, LA JOLLA CA 92037
Carla Reyes officer: Chief Financial Officer 4275 EXECUTIVE SQUARE, SUITE 300, LA JOLLA CA 92037
Yoshio Ishizaka director 4275 EXECUTIVE SQUARE, SUITE 650, LA JOLLA CA 92037
Yutaka Kobayashi director 4275 EXECUTIVE SQUARE, SUITE 650, LA JOLLA CA 92037
Geoffrey Obrien officer: Vice President 4275 EXECUTIVE SQUARE, SUITE 650, LA JOLLA CA 92037

MediciNova (MediciNova) Headlines

From GuruFocus